Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer
Resistance to targeted therapies is an important clinical problem in HER2-positive (HER2+)
breast cancer.“Drug-tolerant persisters”(DTP), a subpopulation of cancer cells that survive
via reversible, nongenetic mechanisms, are implicated in resistance to tyrosine kinase
inhibitors (TKI) in other malignancies, but DTPs following HER2 TKI exposure have not been
well characterized. We found that HER2 TKIs evoke DTPs with a luminal-like or a
mesenchymal-like transcriptome. Lentiviral barcoding/single-cell RNA sequencing reveals …
breast cancer.“Drug-tolerant persisters”(DTP), a subpopulation of cancer cells that survive
via reversible, nongenetic mechanisms, are implicated in resistance to tyrosine kinase
inhibitors (TKI) in other malignancies, but DTPs following HER2 TKI exposure have not been
well characterized. We found that HER2 TKIs evoke DTPs with a luminal-like or a
mesenchymal-like transcriptome. Lentiviral barcoding/single-cell RNA sequencing reveals …
以上显示的是最相近的搜索结果。 查看全部搜索结果